A 2-yr study was conducted to examine the effects of nutritional restriction of beef cows during the last 90 d of gestation on neonatal immunity and production. Cows were fed corn silage, soybean meal diets; dietary treatments consisted of 1) control (CO), 100% of the NRC (1984) requirements for protein and energy, or 2) restricted (RS), 57% of the NRC requirements for energy and protein. All cows received adequate amounts of this diet postpartum. Each year, 26 Angus cows were grouped by age and weight:height ratio (WT:HT) and allotted randomly to treatments. Calves born to dams within each nutritional treatment group were allotted to one of two colostral treatments: 1) colostrum from their dam, or 2) colostrum from a cow from the other nutritional treatment group. Calves from restricted dams had higher cortisol (33.8 vs 26.1 ng/ml) and lower triiodothyronine (T3) (3.82 vs 4.01 ng/ml) concentrations (P less than .05). Maternal nutrition did not affect either colostrum immunoglobulin G (IgG) concentration (43.0 vs 39.5 mg/ml for RS and CO, respectively) or the calves' serum IgG concentration (19.06 vs 20.17 mg/ml IgG at 24 h for RS and CO, respectively). Yet, calves fed colostrum from restricted cows tended to have lower serum IgG concentration (17.2 vs 22.0 mg/ml IgG at 24 h).

N tau-methylhistidine (N tau MH) was used as an index for muscle protein degradation and this index was utilized to evaluate degradation rates in young growing cattle. Initially, two Charolais crossbred heifers, 12 months of age, were used to measure the recovery of radioactivity in the urine for a 120-hour period after intravenous injection of [14C]N tau MH. Of the radioactivity injected into the animals, 89.7% was recovered after 120 hours. With rate and amount of clearance as the criteria, the excretion of N tau MH in urine appears to be a valid index of muscle protein degradation in cattle. Eight steers of two genetic types were used to evaluate the effect of frame size on turnover rates of muscle proteins with N tau MH as an index. Large frame cattle (LG) excreted more N tau MH per day (P less than 0.03) throughout the trial. Total daily creatinine excretion was less for small frame (SM) cattle (P less than 0.02) showing an increase with time (P less than 0.01) in LG and SM cattle. N tau MH-to-creatinine ratios showed a decline with time. Fractional breakdown rates (FBR) and fractional synthesis rates (FSR) appeared to parallel each other with rates tending to decrease with age. No differences were observed between LG and SM cattle for FBR, FSR or fractional growth rate (FGR).

To determine effects of clenbuterol (CB) on muscle protein turnover and growth hormone (GH) secretion, 16 crossbred wether lambs (14.4 kg) were randomized into two groups designated to receive daily oral boluses of gelatin capsules containing corn starch with either 0 (control, CTL) or 1.87 mg/kg body weight CB for either 14 (n = 8) or 28 d (n = 8). This calculates to be approximately 40 mg CB/kg diet. Lambs had ad libitum access to a 16% crude protein corn-soy diet and feed consumption (FC) was measured. After 14 and 28 d, lambs were slaughtered and semitendinosus (ST), longissimus (LD) and brachialis (BR) muscles were exercised, weighed and analyzed for protein (TP) content. For 6 h prior to slaughter of 28-d lambs, 2.5 microCi L-[U-14C]tyrosine/kg was infused intravenously, blood was sampled and plasma was analyzed for specific radioactivity of tyrosine. Plasma GH concentrations were assessed by radioimmunoassay. No differences due to treatment were found in FC, rate of gain or GH concentrations. Semitendinosus and BR weights of control lambs at 14 d did not differ between treatments. At 28 d, ST and BR weights of control lambs (58.8 and 18.5 g, respectively) were less (P less than .10) than those of lambs treated with CB (74.3 and 23.1 g, respectively). The TP per ST and BR at 28 d for control lambs was 71.5 and 85.1% (P less than .10) that of muscles of lambs treated with CB. Fractional protein synthesis rates (FSR) of the BR (9.4 vs 6.1%/d) and total protein synthesized in ST muscle per day (1.4 vs .8 g) were elevated (P less than .10) in lambs treated with CB compared to controls. These data suggest that the increased fractional accretion rate observed in lambs treated with CB for 28 d was caused by increased FSR.

The relationship of serum cortisol to immunoglobulin absorption and gut closure in cesarean-derived neonatal lambs was evaluated in two trials. In trial 1, 21 lambs were obtained on d 136 to 138 of gestation, and in trial 2, 17 lambs were obtained on d 140 to 142 of gestation. At birth, lambs were assigned randomly to four treatments: 1) control (CO), 1 ml saline/kg BW every 4 h; 2) a drug to lower cortisol (LC), 5 mg metyrapone/kg BW every 4 h; 3) single-peak cortisol (SP), 10 IU ACTH/kg BW at 0 h; or 4) elevated cortisol (HC), 5 mg cortisol/kg BW every 4 h in trial 1 or 10 IU ACTH/kg BW every 4 h in trial 2. The treatment period was 24 and 48 h after delivery for trial 1 and 2, respectively. Lambs were fed pooled bovine colostrum every 4 h for 48 h after birth at 2 and 3.5% BW for trial 1 and 2, respectively. Compared with CO, HC increased serum cortisol, LC decreased serum cortisol and SP elevated serum cortisol concentrations through at least 8 h for both trials. In trial 1, HC and SP lambs exhibited elevated serum IgG, IgM and IgA concentrations by 20 h compared with CO. However, no difference in serum immunoglobulin concentration was observed at 36 h among CO, HC and SP. Conversely, LC had the lowest immunoglobulin concentration at 36 and 48 h, and precocious closure to immunoglobulin absorption had occurred by 20 h (P less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)